Your browser doesn't support javascript.
loading
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.
Lonati, Chiara; Baumeister, Philipp; Afferi, Luca; Mari, Andrea; Minervini, Andrea; Krajewski, Wojciech; Azizi, Sosan; Hendricksen, Kees; Martini, Alberto; Necchi, Andrea; Montorsi, Francesco; Briganti, Alberto; Colombo, Renzo; Tafuri, Alessandro; Antonelli, Alessandro; Cerruto, Maria Angela; Rouprêt, Morgan; Masson-Lecomte, Alexandra; Laukhtina, Ekaterina; D'Andrea, David; Shariat, Shahrokh F; Soria, Francesco; Marra, Giancarlo; Gontero, Paolo; Contieri, Roberto; Hurle, Rodolfo; Valiquette, Anne Sophie; Mir, M Carmen; Zamboni, Stefania; Simeone, Claudio; Klatte, Tobias; Teoh, Jeremy Yuen-Chun; Yoshida, Soichiro; Fujii, Yasuhisa; Carando, Roberto; Schulz, Gerald B; Mordasini, Livio; Mattei, Agostino; Moschini, Marco.
Afiliação
  • Lonati C; Department of Urology, Spedali Civili di Brescia, Brescia, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: chiara.lonati@libero.it.
  • Baumeister P; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Afferi L; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Mari A; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, University of Florence, Florence, Italy.
  • Minervini A; Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, University of Florence, Florence, Italy.
  • Krajewski W; Department of Urology and Oncological Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Azizi S; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hendricksen K; Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Martini A; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Necchi A; Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.
  • Montorsi F; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.
  • Briganti A; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.
  • Colombo R; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Tafuri A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Antonelli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Cerruto MA; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
  • Rouprêt M; GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.
  • Masson-Lecomte A; APHP, Department of Urology, Hôpital Saint Louis, Université de Paris, Paris, France.
  • Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • D'Andrea D; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
  • Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urolo
  • Soria F; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
  • Marra G; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
  • Gontero P; Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.
  • Contieri R; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Hurle R; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Valiquette AS; Department of Urology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain.
  • Mir MC; Department of Urology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain.
  • Zamboni S; Department of Urology, Spedali Civili di Brescia, Brescia, Italy.
  • Simeone C; Department of Urology, Spedali Civili di Brescia, Brescia, Italy.
  • Klatte T; Department of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Teoh JY; Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
  • Yoshida S; Department of Urology, Tokyo Medical and Dental University Graduate School, Yushima, Bunkyo-ku, Tokyo, Japan.
  • Fujii Y; Department of Urology, Tokyo Medical and Dental University Graduate School, Yushima, Bunkyo-ku, Tokyo, Japan.
  • Carando R; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Clinica Luganese Moncucco, Lugano, Switzerland; Clinica S. Anna, Swiss Medical Group, Sorengo, Switzerland; Clinica Santa Chiara, Locarno, Switzerland.
  • Schulz GB; Department of Urology, Ludwig-Maximilians-University, Munich, Germany.
  • Mordasini L; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Mattei A; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Moschini M; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Eur Urol Focus ; 8(5): 1270-1277, 2022 09.
Article em En | MEDLINE | ID: mdl-34419381
ABSTRACT

BACKGROUND:

Literature lacks clear evidence regarding the optimal treatment for non-muscle-invasive micropapillary bladder cancer (MPBC) due to its rarity and the presence of only small sample size and single-centre studies.

OBJECTIVE:

To assess cancer-specific mortality (CSM) and overall mortality (OM) between immediate radical cystectomy (RC) and conservative management among T1 high-grade (HG) MPBC. DESIGN, SETTING, AND

PARTICIPANTS:

We retrospectively analysed a multicentre dataset including 119 T1 HG MPBC patients treated between 2005 and 2019 at 15 tertiary referral centres. The median follow-up time was 35 mo (interquartile range 19-64). INTERVENTION Patients underwent immediate RC versus conservative management with bacillus Calmette-Guérin. OUTCOMES MEASUREMENTS AND STATISTICAL

ANALYSIS:

Cumulative incidence functions and Kaplan-Meier methods were applied to estimate survival outcomes. Multivariable Cox analyses were performed to assess independent predictors of disease recurrence and disease progression after conservative management; covariates consisted of pure MPBC, concomitant lymphovascular invasion (LVI), and carcinoma in situ at initial diagnosis. RESULTS AND

LIMITATIONS:

Immediate RC and conservative management were performed in 27% and 73% of patients, respectively. CSM and OM did not differ significantly among patient treated with immediate RC versus conservative management (Pepe-Mori test p = 0.5 and log-rank test p = 0.9, respectively). Overall, 66.7% and 34.5% of patients experienced disease recurrence and disease progression after conservative management, respectively. At multivariable Cox analyses, concomitant LVI was an independent predictor of disease recurrence (p = 0.01) and progression (p = 0.03), while pure MPBC was independently associated with disease progression (p = 0.03). The absence of a centralised re-review and the retrospective design represent the main limitations of our study.

CONCLUSIONS:

Conservative management could achieve satisfactory results among T1 HG MPBC patients with neither pure MPBC nor LVI at initial diagnosis. PATIENT

SUMMARY:

Bacillus Calmette-Guérin seems to be an effective therapy for T1 micropapillary bladder cancer patients with neither pure micropapillary disease nor lymphovascular invasion at initial diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma Papilar Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Focus Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma Papilar Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Focus Ano de publicação: 2022 Tipo de documento: Article
...